SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim") announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon "Poster of Distinction" award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD). The Company's award-winning research showcased a physiologically relevant system built from primary human cells derived from both healthy donors and patients with Ulcer

10-K - VivoSim Labs, INC. (0001497253) (Filer)

8-K - VivoSim Labs, INC. (0001497253) (Filer)